Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

While many intracellular signaling pathways lead from the cell surface ... More information: Eyal Zoler et al, Promiscuous Janus kinase binding to cytokine receptors modulates signaling ...

Janus kinase (JAK) inhibitors are an important treatment option for people with chronic inflammatory diseases such as ...

A logical first approach might be to target appropriate members of the Janus kinase (JAK) family or the signal transducers and activators of transcription (STAT) family, as these proteins are ...

Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering. The "Janus Kinase (JAK ...

ATOPIC dermatitis (AD) is the most common chronic inflammatory skin condition, affecting up to 10% of adults and up to 20% of ...

Dizal announces new findings on golidocitinib; to present clinical results at ELCC 2025 in Paris on March 26-29: Shanghai Saturday, March 22, 2025, 17:00 Hrs [IST] Dizal, a biopha ...

ORLANDO, Fla. — Dosing of the oral Janus kinase (JAK) inhibitor upadacitinib can be increased or decreased in adult patients with moderate to severe atopic dermatitis (AD) to achieve the desired ...

Janus kinase (JAK) inhibitors have revolutionized ... of interleukin-7 and the thymic stromal lymphopoietin (TSLP) pathway, potentially bringing a novel approach to the control of AA, according ...

Golidocitinib is a JAK1 only inhibitor approved for the treatment of relapsed or refractory PTCL The combination of ...

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis ...